What are the 2026 American Diabetes Association (ADA) guideline updates for the management of adults with type 2 diabetes?

ADA 2026 Diabetes Guidelines Updates

The 2026 ADA guidelines continue to emphasize a comorbidity-driven approach to type 2 diabetes management, prioritizing SGLT2 inhibitors and GLP-1 receptor agonists based on cardiovascular and renal disease presence, with expanded recognition of dual GIP/GLP-1 agonists and metabolic dysfunction-associated steatotic liver disease (MASLD) management. 1

Core Treatment Philosophy

The 2026 guidelines maintain the shift away from purely glucose-centric management toward outcome-driven therapy that reduces mortality and morbidity. The framework prioritizes:

• Person-centered shared decision-making considering cardiovascular/renal comorbidities, effectiveness, hypoglycemia risk, weight impact, cost/access, adverse reactions, and patient preferences 2, 1
• Early combination therapy at diagnosis to shorten time to glycemic goals 2, 1
• Medication reassessment every 3-6 months with adjustments based on treatment-specific factors 2, 1

Disease-Specific Medication Selection

For Patients WITH Heart Failure (HFrEF or HFpEF)

Use SGLT2 inhibitors regardless of A1C level for both glycemic management and prevention of HF hospitalizations. This recommendation applies to both reduced and preserved ejection fraction 2, 3, 1. The cardiovascular mortality benefit supersedes glycemic considerations.

For Patients WITH Chronic Kidney Disease

The approach stratifies by eGFR:

• eGFR 20-60 mL/min/1.73 m² or albuminuria: Use SGLT2 inhibitor OR GLP-1 RA (with demonstrated CKD benefit) regardless of A1C for slowing CKD progression and reducing cardiovascular events 2, 3, 1

  • Critical caveat: SGLT2 inhibitor glycemic benefits diminish at eGFR <45 mL/min/1.73 m² 2, 3

• eGFR <30 mL/min/1.73 m² (advanced CKD): Prefer GLP-1 RA due to lower hypoglycemia risk and cardiovascular event reduction 2, 3, 1

For Patients WITH Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

New in 2026: For patients with MASLD plus overweight/obesity, consider GLP-1 RA or dual GIP/GLP-1 RA for glycemic management and weight loss 3, 1

For biopsy-proven MASH or high fibrosis risk: Prefer pioglitazone, GLP-1 RA, or dual GIP/GLP-1 RA for glycemic management 3, 1

This represents an important expansion recognizing liver disease as a treatment-directing comorbidity.

For Patients WITHOUT Cardiovascular/Kidney Disease

Address both glycemic AND weight goals simultaneously 2, 1. When patients haven't achieved weight goals, intensify with:

• Lifestyle modifications
• Structured weight management programs
• Pharmacologic agents
• Metabolic surgery (as appropriate) 2

The glucose-lowering plan should inherently support weight management goals 2.

Insulin Use: When and How

Indications for Insulin Initiation

Start insulin immediately when:

• Evidence of catabolism (unexpected weight loss)
• Symptomatic hyperglycemia
• A1C >10% (>86 mmol/mol) OR blood glucose ≥300 mg/dL (≥16.7 mmol/L) 2

This applies regardless of background therapy or disease stage.

Critical Hierarchy Change

GLP-1 RA (including dual GIP/GLP-1 RA) is preferred over insulin when intensification is needed 2, 1. This represents a fundamental shift prioritizing agents with:

• Lower hypoglycemia risk
• Weight loss vs. weight gain
• Cardiovascular benefits

If insulin is used: Combine with GLP-1 RA or dual GIP/GLP-1 RA for greater glycemic effectiveness, beneficial weight effects, and reduced hypoglycemia risk 2, 1. Reassess insulin dosing upon GLP-1 RA addition or dose escalation.

Continuation of Other Agents

Glucose-lowering agents may be continued when starting insulin unless contraindicated or not tolerated 2, 1.

Dual GIP/GLP-1 Receptor Agonists

The 2026 guidelines explicitly incorporate dual GIP/GLP-1 agonists (tirzepatide) throughout recommendations, recognizing them as equivalent or superior alternatives to traditional GLP-1 RAs for:

• Glycemic management 2, 3, 1
• Weight management 3, 1
• MASLD/MASH treatment 3, 1
• Combination with insulin 2

Key Pitfalls to Avoid

1. Don't use SGLT2 inhibitors for glycemic benefit alone at eGFR <45: The glucose-lowering effect is substantially reduced, though cardiovascular/renal benefits persist 2, 3

2. Don't default to insulin when GLP-1 RA is appropriate: The evidence strongly favors GLP-1 RA/dual agonists over insulin for most intensification scenarios 2

3. Don't ignore comorbidities when selecting therapy: The presence of HF, CKD, or MASLD should drive medication choice independent of A1C levels 2, 3, 1

4. Don't forget to reduce insulin when adding GLP-1 RA: Failure to adjust insulin dosing increases hypoglycemia risk 2

Evidence Quality Considerations

The 2026 recommendations are based primarily on 2024-2025 ADA Standards of Care 2, 3, 1, representing the highest-quality guideline evidence. These supersede older guidelines like the 2017 ACP recommendations 4 which predate the cardiovascular and renal outcome trials that fundamentally changed diabetes management. The 2022 AACE guidelines 5 align with ADA on comorbidity-driven approaches, and the 2024 ACP systematic review 6 confirms mortality and cardiovascular benefits of SGLT2 inhibitors and GLP-1 agonists.

The strength of this approach lies in prioritizing hard outcomes (mortality, cardiovascular events, CKD progression, HF hospitalizations) over surrogate markers (A1C alone), fundamentally improving quality of life and survival for patients with type 2 diabetes.